Related Experiment Video
Updated: Dec 3, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Circulating microRNA-145 as a diagnostic biomarker for non-small-cell lung cancer: A systemic review and
Shaohua Tao1, Xuegui Ju2, Hui Zhou1
1Department of Respiratory and Critical Care Medicine, Affiliated Hospital/Clinical College, Chengdu University, Chengdu, China.
Background:
MicroRNAs (miRNAs), a class of small non-coding, highly stable RNAs, have been reported to have diagnostic value for variety types of cancers.
Objectives:
To assess the diagnostic value of circulating miR-145 for non-small cell lung cancer (NSCLC) by using systemic review and meta-analysis.
Methods:
A systematic literature search was conducted in five databases until 20 February 2020 to identify diagnostic trials of miR-145 in the diagnosis of NSCLC. The quality of included studies was assessed by the QUADAS-2 tool with Review Manager 5.3, and the summary receiver operating characteristic (SROC) curve was plotted by STATA 13.1 software.
Results:
A total of 1394 patients from 11 data sets in trials (published in nine studies) were recruited. The area under the curve of the SROC was 0.83. According to the meta regression, the specimen selection was considered the source of heterogeneity, the SROC in serum (0.90 (95% CI 0.87, 0.92), the sensitivity was 0.84 (95% CI 0.79, 0.89), and the specificity was 0.80 (95% CI 0.71, 0.89)) was obviously higher than that in plasma (SROC=0.75).
Conclusion:
Serum miR-145 might be served as a potentially useful biomarker for NSCLC diagnosis. However, due to the existing limited-quality research, more large-scale and multicenter studies are required for further verification.
More Related Videos
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
01:22MicroRNAs
01:22MicroRNAs